^
    CANCER:

    Penile Cancer

    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    No biomarker
    Penile Cancer
    paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    cetuximab
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    cisplatin
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    5-fluorouracil + mitomycin
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    carboplatin + paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    cisplatin + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    cisplatin + 5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    imiquimod
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Penile Cancer
    TIP
    Sensitive
    :
    A2
    MSI-H/dMMR
    Penile Cancer
    pembrolizumab
    Sensitive
    :
    A2
    TMB-H
    Penile Cancer
    pembrolizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Penile Cancer
    pembrolizumab
    Sensitive
    :
    C1
    TMB-H + PD-L1 expression + MSI-L/dMMR
    Penile Cancer
    nivolumab + ipilimumab
    Sensitive
    :
    C4
    TMB-H + PD-L1 expression
    Penile Cancer
    toripalimab
    Sensitive
    :
    C4
    CDKN2A mutation
    Penile Cancer
    nivolumab
    Sensitive
    :
    C4